KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Debt (2016)

Vertex Pharmaceuticals has reported Total Debt over the past 6 years, most recently at $300.0 million for Q4 2016.

  • Quarterly results put Total Debt at $300.0 million for Q4 2016, up 1.64% from a year ago — trailing twelve months through Dec 2016 was $300.0 million (up 1.64% YoY), and the annual figure for FY2016 was $300.0 million, up 1.64%.
  • Total Debt for Q4 2016 was $300.0 million at Vertex Pharmaceuticals, up from $297.8 million in the prior quarter.
  • Over the last five years, Total Debt for VRTX hit a ceiling of $300.0 million in Q4 2016 and a floor of $294.7 million in Q3 2014.
  • Median Total Debt over the past 3 years was $295.0 million (2015), compared with a mean of $295.9 million.
  • Biggest five-year swings in Total Debt: rose 0.03% in 2015 and later increased 1.64% in 2016.
  • Vertex Pharmaceuticals' Total Debt stood at $294.8 million in 2014, then rose by 0.13% to $295.2 million in 2015, then increased by 1.64% to $300.0 million in 2016.
  • The last three reported values for Total Debt were $300.0 million (Q4 2016), $297.8 million (Q3 2016), and $296.5 million (Q2 2016) per Business Quant data.